Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 10Active not recruiting 8Terminated 2Recruiting 2Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 31INDUSTRY 20NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Multiple Myeloma 2Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia 1

Interventions

Cyclophosphamide 47aldesleukin 30fludarabine phosphate 26fludarabine 24Carboplatin 18Rituximab 16Interleukin-2 16Cisplatin 16Bevacizumab 162,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 16Radiotherapy 15Paclitaxel 15Magnetic Resonance Spectroscopy 14Bortezomib 14Filgrastim 13Doxorubicin 13Oxaliplatin 12Erlotinib Hydrochloride 12Trastuzumab 11Leucovorin 11Etoposide 11Biopsy 11Taxes 10Radiation 10Fluorouracil 10alvocidib 9Specimen Handling 9Sorafenib 9Docetaxel 9Dexamethasone 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × NIH × liposomal doxorubicin × Clear all
NCT00074490 2018-12-31

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
442 enrolled 17 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT01078441 2015-01-12

Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant

National Cancer Institute (NCI)

Phase 2 Terminated
2 enrolled 5 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡